FDA warns about non-GRAS cold products
This article was originally published in The Tan Sheet
Boca Pharmacal markets OTCs containing prescription ingredients, making them products not generally recognized as safe and effective for use. In in a July 22 warning letter to the Coral Spring, Fla-based firm, FDA says the labels of the products - Pseudo DM GG Syrup and C-Phen DM Drops - suggest they diagnose, cure, mitigate, treat or prevent disease, although the drugs do not have approved applications. The agency adds the drugs are mislabeled for consumer use because the Rx ingredients are indicated for conditions that are not "amenable to self-diagnosis and treatment of individuals who are not medical practitioners." Boca, which contracted another firm to manufacture the products, has 15 days from receipt of the warning to notify FDA of its work to correct the violations and prevent a recurrence. The warning letter posted Sept. 20 on FDA's website does not identify the contract manufacturer
You may also be interested in...
“Responsible” CBD supplement marketers are disadvantaged against “bad actors” with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.
With makeup and lipstick sales down globally at a time of wide mask use, Shiseido is focused on skin health, planning launches to address sensitive skin needs and heightened demand for cleansing and protection effects. In August, the firm projected a 16% decline in net sales for full-year fiscal 2020.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.